Wells Fargo raised the firm’s price target on Insmed (INSM) to $119 from $107 and keeps an Overweight rating on the shares. As the firm expected, the treprostinil palmitil inhalation powder Phase 2 readout is a clear win. The data significantly strengthened TPIP’s potential to become the alternative/ go-to inhaled prostacyclin in pulmonary arterial hypertension, Wells adds.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $110 from $92 at Stifel
- Insmed’s TPIP Program: Promising Phase 2 Results and Market Potential Drive Buy Rating
- United Therapeutics price target lowered to $315 from $321 at BofA
- Liquidia price target lowered to $23 from $25 at BofA
- Jefferies ups Insmed target on ‘blue sky scenario’ PAH data